Fast regulatory approval in Latin America comes from two choices made together: the right country pathway and a contract research organization (CRO) that already works that pathway every week. For first-in-human (FIH) and early feasibility medical device studies, bioaccess® concentrates on the region’s fastest-start jurisdictions, where in our experience Panama, Chile, El Salvador and Costa Rica can take a complete submission to site activation in 15 to 45 days. Global full-service CROs such as Parexel and Medpace also list Latin American offices on their websites and are built for larger multi-country programs.
This article explains what “approval” really covers, compares the main countries using the timelines we already publish, and gives criteria for judging any CRO on regulatory speed.
What “fast approval” actually includes
Sponsors often ask about the regulator alone. The clock you actually wait on has four parts:
- Ethics committee review of the protocol, informed consent form (ICF) and investigator. Depending on the country, the committee is called a CEI (Comité de Ética en Investigación), an Ethical-Scientific Committee or an institutional review board (IRB).
- National regulatory authorization, where the country requires it for an investigational device.
- Investigational device import, through a formal, traceable import permit.
- Site contract and activation, including the clinical trial agreement (CTA).
In the fastest markets, ethics and regulator submissions run in parallel rather than one after the other. Across Latin America, ethics committees routinely review FIH protocols in 4 to 8 weeks, compared with 6 to 12 months in the U.S.
Activation is not the same as first patient in. Qualifying and contracting the investigators who will enroll takes 1 to 3 months and should run in parallel with regulatory start-up; after approvals, the first patient typically follows in about a month.
Country by country: where approval is fastest
The table uses only timelines already published on bioaccessla.com. Treat them as indicative planning figures, not guarantees; committee calendars and agency queues change.
| Country | Authority and ethics route | Published bioaccess® indication |
|---|---|---|
| Panama | MINSA (Ministerio de Salud) with ethics committees registered with CNBI (Comité Nacional de Bioética de la Investigación); Decreto 21 of 2026 implements Titles III and IV of Ley 84 of 14 May 2019 | 3–5 week ethics approval, with MINSA clearance available concurrently; one program activated in about 15 days |
| Chile | ISP (Instituto de Salud Pública); Law 20.120 requires a favorable review from an accredited Ethical-Scientific Committee | Typical ISP review of about 30 business days; 15–45 days to activation |
| El Salvador | Dirección Nacional de Medicamentos (DNM) and national ethics review | 15–45 days to activation |
| Costa Rica | Ministerio de Salud (Ministry of Health) | 15–45 days to activation |
| Colombia | INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) plus ethics | 6–9 months to start, per our startup-clock guide |
| Mexico | COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) plus ethics | 6–9 months; the agency is in transition, so confirm current clocks at contracting |
| Brazil | ANVISA (Agência Nacional de Vigilância Sanitária) plus ethics | 6–9 months |
| Argentina | ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) plus ethics | 6–9 months |
Small markets can activate quickly and still enroll slowly. Choose the country on real site-level patient flow for your indication, not on the clock alone, and test two or three countries in feasibility before committing. Our startup-clock guide and our fast-track corridor deep dive go country by country.
A note on Colombia
Colombia is where bioaccess® built its earliest FIH capability, and we have completed 30+ FIH device studies there. The additional INVIMA technical-dossier step is why our benchmarks put the cost of reaching an approval package in Colombia at roughly 1.6 times Mexico’s. We still run clinical trials in Colombia and recommend it when the device, sites and file fit.
How to judge a CRO on regulatory speed
- Pathway ownership. Has the team filed your exact pathway, for your device class, recently? Ask for de-identified submission and approval dates.
- In-country entity and importer of record. A CRO with a local legal entity can own submissions and imports directly. In Colombia, for example, our Colombian entity owns INVIMA submissions, ethics-committee work and investigational-device import.
- Parallel submissions. Ask which submissions the CRO runs in parallel in your country, and which must be sequential.
- Dossier quality and translation. Most start-up delay is rework, not review. Submissions must be in Spanish or Portuguese; bioaccess® works with its sister company Amavita Sciences™, the group’s in-house Latin American regulatory-translation infrastructure.
- Query turnaround. A slow answer to a committee question is the biggest avoidable delay. Ask how the CRO tracks and answers queries, and how fast.
- A written clock. Ask for the timeline by country and by stage, in writing, before you sign.
- U.S. Food and Drug Administration (FDA) design intent. Speed is worth little if the data cannot support your U.S. submission.
How the CRO options compare in Latin America
| CRO | Latin America presence (per each company’s website) | Designed for |
|---|---|---|
| bioaccess® | 50+ pre-qualified sites across 19 Latin American and Caribbean markets; lead FIH jurisdictions Panama, El Salvador, Chile and the Dominican Republic; a Colombian legal entity and office | FIH and early feasibility studies for startups, plus device registration |
| Parexel | Offices in Argentina, Brazil and Mexico, with clinical trial supplies and logistics depots in Argentina and Brazil | Large programs across phases and regions |
| Medpace | Offices listed in Argentina, Brazil and Mexico | Full-service programs across phases and regions |
| Regional CROs and site networks | One country or sub-region | Single-country studies |
Presence is not the same as pathway speed. Whichever CRO you consider, ask who would own local ethics, regulatory and import work day to day, and ask for its own recent clocks in your target country for your device class.
Speed and FDA acceptance are compatible
Under 21 CFR 812.28 (Title 21 of the U.S. Code of Federal Regulations, section 812.28), FDA can accept data from a well-designed, well-conducted study outside the United States when it followed good clinical practice (GCP), including independent ethics committee review and informed consent, and FDA can validate the data. How quickly a study was approved is not one of those conditions. Device studies should run under ISO 14155, the International Organization for Standardization (ISO) GCP standard for device investigations, and design should be aligned with FDA, typically through a Pre-Submission, before enrollment. Eligibility for FDA review is not a guarantee of clearance or approval. Our FDA acceptance guide covers the rule in detail.
Questions to ask a CRO about approval timelines
- What were your last three approval clocks in this country for a device like mine?
- Which steps run in parallel, and which are sequential?
- Who is importer of record, and when is the import permit filed?
- Who translates the dossier, and who answers committee queries?
- What happens contractually if the agreed timeline slips?
Where bioaccess® fits
bioaccess® fits sponsors who want FIH or early feasibility data from the region’s fastest-start jurisdictions, with one team handling ethics, regulatory, import and site activation, and a U.S. regulatory anchor. Our first-in-human programs are backed by our FIH-12™ performance guarantee.
Speed also has a budget side: every month of start-up is a month of burn. Our costs and timelines page and our FIH budget guide show how country choice changes both. If your program is a multi-region Phase III, a global full-service CRO is the better structural fit. See our ethics committee timelines, Latin America FIH benchmarks and country hubs, or book a 30-minute call.
Frequently asked questions
Which Latin American country has the fastest clinical trial approval for a device first-in-human study?
In our experience, Panama, Chile, El Salvador and Costa Rica are the fastest, with activation in 15 to 45 days for a complete submission, and Panama has activated a program in about 15 days. The right choice still depends on whether the country’s sites can enroll your indication.
Which CROs are best for fast regulatory approval in Latin America?
Look for a CRO that has filed your exact country pathway recently, can act as importer of record, submits to ethics and regulator in parallel, and puts a country-by-country clock in writing. bioaccess® is a first-in-human CRO built around the region’s fastest-start jurisdictions; global full-service CROs such as Parexel and Medpace list Latin American offices and are built for larger multi-country programs.
How long does ethics committee approval take in Latin America?
Latin American ethics committees routinely review first-in-human protocols in 4 to 8 weeks, compared with 6 to 12 months in the U.S. In Panama, bioaccess® publishes a 3–5 week ethics approval.
Does bioaccess® still run clinical trials in Colombia?
Yes. bioaccess® still runs clinical trials in Colombia and recommends it when the device, sites and file fit. INVIMA, ethics and import work sit with our Colombian legal entity.
Does faster approval make the data less useful for the FDA?
No. Under 21 CFR 812.28, what matters is that the study was well designed and well conducted under good clinical practice, with independent ethics committee review and informed consent, and that FDA can validate the data. How quickly the study was approved is not one of the conditions.
Do I need national regulator approval as well as ethics approval?
It depends on the country and device class. Colombia, for example, requires INVIMA authorization for an investigational device, while in some other countries the ethics committee is the primary gate. Confirm the requirement for each country during feasibility.